Drug Type Biosimilar, Colony-stimulating factors |
Synonyms Filgrastim Biosimilar (Tanvex BioPharma, Inc.), 非格司亭 生物类似药(Tanvex BioPharma, Inc.), TX-01 + [1] |
Target |
Action agonists |
Mechanism CSF-3R agonists(Colony stimulating factor 3 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Canada (01 Oct 2021), |
Regulation- |

| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | Filgrastim-txid |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Febrile Neutropenia | United States | 28 Jun 2024 | |
| Stem cell mobilisation | United States | 28 Jun 2024 | |
| Neutropenia | Canada | 01 Oct 2021 |






